Pfizer Inc. (PFE) Financial Statements

Executive TeamFinancials
SegmentsShareholders

Pfizer financial statements at a glance

Pfizer reported revenue of $62.58 billion for fiscal year 2025 (ended December 31, 2025), down 1.6% from fiscal year 2024. Net income was $7.77 billion, a net margin of 12.4%, and diluted earnings per share were $1.36.

At the end of fiscal year 2025 it had total assets of $208.16 billion, total liabilities of $121.39 billion and shareholders' equity of $86.48 billion, with cash and short-term investments of $13.60 billion and total debt of $63.96 billion.

Its operations brought in $11.70 billion of cash; capital spending was $2.63 billion, leaving free cash flow of $9.08 billion.

The tables below show the income statement, balance sheet and cash flow statement; the key figures of the last 5 fiscal years are at the bottom of the page.

Figures from company filings, in USD; latest fiscal year ended December 31, 2025.

PFE logo

Pfizer Inc.

PFEUnited States
Healthcare
USD (Local)

Income Statement

Annual • USD

Total Revenue
62.58B
Prev Year: 63.63B
YoY: -1.6%
Operating Revenue
62.58B
Prev Year: 63.63B
YoY: -1.6%
Total Unusual Items Excluding Goodwill
-8.96B
Prev Year: -5.34B
YoY: -67.9%
Total Unusual Items
-8.96B
Prev Year: -5.34B
YoY: -67.9%
Normalized EBITDA
25.75B
Prev Year: 23.47B
YoY: +9.7%
Tax Rate for Calcs
0.21
Prev Year: 0
Tax Effect of Unusual Items
-1.88B
Prev Year: -1.12B
YoY: -67.9%
Noncontrolling Interests
-41.00M
Prev Year: -31.00M
YoY: -32.3%
Depreciation Amortization Depletion
4.87B
Prev Year: 5.29B
YoY: -7.8%
Depreciation and amortization
4.87B
Prev Year: 5.29B
YoY: -7.8%
Amortization
4.87B
Prev Year: 5.29B
YoY: -7.8%
Amortization of Intangibles
4.87B
Prev Year: 5.29B
YoY: -7.8%
Cost of Revenue
16.07B
Prev Year: 17.85B
YoY: -10.0%
Gross Profit
46.51B
Prev Year: 45.78B
YoY: +1.6%
Operating Expense
29.11B
Prev Year: 30.84B
YoY: -5.6%
Selling General and Administrative
13.79B
Prev Year: 14.73B
YoY: -6.4%
Research and Development
10.44B
Prev Year: 10.82B
YoY: -3.6%
Operating Income
17.41B
Prev Year: 14.94B
YoY: +16.5%
Net Non Operating Interest Income Expense
-2.07B
Prev Year: -2.55B
YoY: +18.8%
Non-operating Interest Income
603.00M
Prev Year: 545.00M
YoY: +10.6%
Non-operating Interest Expense
2.67B
Prev Year: 3.09B
YoY: -13.6%
Other Income Expense
-7.82B
Prev Year: -4.37B
YoY: -79.0%
Gain on Sale of Securities
198.00M
Prev Year: 1.01B
YoY: -80.4%
Special Income Charges
-9.16B
Prev Year: -6.35B
YoY: -44.3%
Restructuring and Mergers Acquisition
1.55B
Prev Year: 1.99B
YoY: -22.0%
Impairment of Capital Assets
4.94B
Prev Year: 3.29B
YoY: +49.9%
Other Special Charges
2.67B
Prev Year: 633.00M
YoY: +321.8%
Other Non-operating Income (expense)
1.14B
Prev Year: 868.00M
YoY: +31.7%
Pre-tax Income
7.52B
Prev Year: 8.02B
YoY: -6.3%
Provision for Income Taxes
-266.00M
Prev Year: -28.00M
YoY: -850.0%
Net Income Common Stockholders
7.77B
Prev Year: 8.03B
YoY: -3.2%
Net Income
7.77B
Prev Year: 8.03B
YoY: -3.2%
Net Income Including Non-Controlling Interests
7.81B
Prev Year: 8.06B
YoY: -3.1%
Net Income from Continuing Operations
7.79B
Prev Year: 8.05B
YoY: -3.3%
Net Income from Discontinued Operations
25.00M
Prev Year: 11.00M
YoY: +127.3%
Diluted NI Available to Com Stockholders
7.77B
Prev Year: 8.03B
YoY: -3.2%
Average Dilution Earnings
-
Basic EPS
1.37
Prev Year: 1.42
YoY: -3.5%
Diluted EPS
1.36
Prev Year: 1.41
YoY: -3.5%
Weighted Average Shares (basic)
5.68B
Prev Year: 5.66B
YoY: +0.3%
Weighted Average Shares (diluted)
5.71B
Prev Year: 5.70B
YoY: +0.2%
Total Expenses
45.17B
Prev Year: 48.69B
YoY: -7.2%
Net Income from Continuing and Discontinued Operation
7.77B
Prev Year: 8.03B
YoY: -3.2%
Normalized Income
14.83B
Prev Year: 12.24B
YoY: +21.1%
Interest Income
603.00M
Prev Year: 545.00M
YoY: +10.6%
Interest Expense
2.67B
Prev Year: 3.09B
YoY: -13.6%
Net Interest Income
-2.07B
Prev Year: -2.55B
YoY: +18.8%
EBIT
10.19B
Prev Year: 11.11B
YoY: -8.3%
EBITDA
16.78B
Prev Year: 18.13B
YoY: -7.4%
Reconciled Cost of Revenue
14.35B
Prev Year: 16.12B
YoY: -11.0%
Reconciled Depreciation
6.59B
Prev Year: 7.01B
YoY: -6.0%
Net Income from Continuing Operation Net Minority Interest
7.75B
Prev Year: 8.02B
YoY: -3.4%
Values in USD

Pfizer key figures by fiscal year

FY2025FY2024FY2023FY2022FY2021
Revenue$62.6B$63.6B$59.6B$101.2B$81.3B
Gross profit$46.5B$45.8B$34.6B$66.8B$50.5B
Operating income$17.4B$14.9B$4.4B$38.1B$23.7B
Net income$7.8B$8.0B$2.1B$31.4B$22.0B
Diluted EPS$1.36$1.41$0.37$5.47$3.85
Total assets$208.2B$213.4B$226.5B$197.2B$181.5B
Total liabilities$121.4B$124.9B$137.2B$101.3B$104.0B
Shareholders' equity$86.5B$88.2B$89.0B$95.7B$77.2B
Cash and short-term investments$13.6B$20.5B$12.7B$22.7B$31.1B
Total debt$64.0B$63.6B$70.8B$34.9B$37.0B
Operating cash flow$11.7B$12.7B$8.7B$29.3B$32.6B
Capital spending$2.6B$2.9B$3.9B$3.2B$2.7B
Free cash flow$9.1B$9.8B$4.8B$26.0B$29.9B

In USD. Fiscal years as reported by the company; statements on this page go back to fiscal year 2014.

Questions and answers

What was Pfizer's revenue in fiscal year 2025?

$62.58 billion, down 1.6% from $63.63 billion in fiscal year 2024.

How much profit does Pfizer make?

Pfizer reported net income of $7.77 billion for fiscal year 2025 (12.4% of revenue); operating income was $17.41 billion.

How much cash and debt does Pfizer have?

At the end of fiscal year 2025: cash and short-term investments of $13.60 billion and total debt of $63.96 billion.

What is Pfizer's free cash flow?

$9.08 billion in fiscal year 2025 (operating cash flow of $11.70 billion minus capital spending of $2.63 billion).

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.
LinkedInLinkedInXXYouTubeYouTube